O Kenrik Duru1, Norman Turk2, Susan L Ettner2,3, Romain Neugebauer4, Tannaz Moin5,6, Jinnan Li2, Lindsay Kimbro2, Charles Chan7, Robert H Luchs7, Abigail M Keckhafer7, Anya Kirvan7, Sam Ho7, Carol M Mangione2,3. 1. David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA. kduru@mednet.ucla.edu. 2. David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA. 3. Fielding School of Public Health, University of California, Los Angeles, CA, USA. 4. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 5. VA HSR&D Center for the Study of Healthcare Innovation, Implementation, and Policy, Los Angeles, CA, USA. 6. VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 7. UnitedHealthcare, Minnetonka, MN, USA.
Abstract
BACKGROUND: Reducing patient cost-sharing and engaging patients in disease management activities have been shown to increase uptake of evidence-based care. OBJECTIVE: To evaluate the effect of employer purchase of a disease-specific plan with reduced cost-sharing and disease management (the Diabetes Health Plan/DHP) on medication adherence among eligible employees and dependents. DESIGN: Employer-level "intent to treat" cohort study, including data from eligible employees and their dependents with diabetes, regardless of whether they were enrolled in the DHP. SETTING: Employers that contracted with a large national health plan administrator in 2009, 2010, and/or 2011. PARTICIPANTS: Ten employers that purchased the DHP and 191 employers that did not (controls). Inverse probability weighting (IPW) estimation was used to adjust for inter-group differences. INTERVENTION: The DHP includes free or low-cost medications and physician visits. Enrollment strategies and specific benefit designs are determined by the employer and vary in practice. DHP participants are notified up front that they must engage in their own health care (e.g., receiving diabetes-related screening) in order to remain enrolled. MAIN OUTCOME MEASURE: Mean employee adherence to metformin, statins, and ACE/ARBs at the employer level at one year post-DHP implementation, as measured by the proportion of days covered (PDC). RESULTS: Baseline adherence to the three medications was similar across DHP and control employers, ranging from 64 to 69 %. In the first year after DHP implementation, predicted employer-level adherence for metformin (+4.9 percentage points, p = 0.017), statins (+4.8, p = 0.019), and ACE/ARBs (+4.4, p = 0.02) was higher with DHP purchase. LIMITATIONS: Non-randomized, observational study. CONCLUSIONS: The Diabetes Health Plan, an innovative health plan that combines reduced cost-sharing and disease management with an up-front requirement of enrollee participation in his or her own health care, is associated with a modest improvement in medication adherence at 12 months.
BACKGROUND: Reducing patient cost-sharing and engaging patients in disease management activities have been shown to increase uptake of evidence-based care. OBJECTIVE: To evaluate the effect of employer purchase of a disease-specific plan with reduced cost-sharing and disease management (the Diabetes Health Plan/DHP) on medication adherence among eligible employees and dependents. DESIGN: Employer-level "intent to treat" cohort study, including data from eligible employees and their dependents with diabetes, regardless of whether they were enrolled in the DHP. SETTING: Employers that contracted with a large national health plan administrator in 2009, 2010, and/or 2011. PARTICIPANTS: Ten employers that purchased the DHP and 191 employers that did not (controls). Inverse probability weighting (IPW) estimation was used to adjust for inter-group differences. INTERVENTION: The DHP includes free or low-cost medications and physician visits. Enrollment strategies and specific benefit designs are determined by the employer and vary in practice. DHPparticipants are notified up front that they must engage in their own health care (e.g., receiving diabetes-related screening) in order to remain enrolled. MAIN OUTCOME MEASURE: Mean employee adherence to metformin, statins, and ACE/ARBs at the employer level at one year post-DHP implementation, as measured by the proportion of days covered (PDC). RESULTS: Baseline adherence to the three medications was similar across DHP and control employers, ranging from 64 to 69 %. In the first year after DHP implementation, predicted employer-level adherence for metformin (+4.9 percentage points, p = 0.017), statins (+4.8, p = 0.019), and ACE/ARBs (+4.4, p = 0.02) was higher with DHP purchase. LIMITATIONS: Non-randomized, observational study. CONCLUSIONS: The Diabetes Health Plan, an innovative health plan that combines reduced cost-sharing and disease management with an up-front requirement of enrollee participation in his or her own health care, is associated with a modest improvement in medication adherence at 12 months.
Authors: Ashish K Jha; Ronald E Aubert; Jianying Yao; J Russell Teagarden; Robert S Epstein Journal: Health Aff (Millwood) Date: 2012-08 Impact factor: 6.301
Authors: Lindsay B Kimbro; Jinnan Li; Norman Turk; Susan L Ettner; Tannaz Moin; Carol M Mangione; O Kenrik Duru Journal: Am J Manag Care Date: 2014-08-01 Impact factor: 2.229
Authors: Ginger S Carls; M Christopher Roebuck; Troyen A Brennan; Julie A Slezak; Olga S Matlin; Teresa B Gibson Journal: J Occup Environ Med Date: 2012-07 Impact factor: 2.162
Authors: O Kenrik Duru; Carol M Mangione; Charles Chan; Abigail Keckhafer; Lindsay Kimbro; K Anya Kirvan; Norman Turk; Robert Luchs; Jinnan Li; Susan Ettner Journal: Prev Chronic Dis Date: 2013 Impact factor: 2.830
Authors: Mohammed K Ali; Frank Wharam; O Kenrik Duru; Julie Schmittdiel; Ronald T Ackermann; Jeanine Albu; Dennis Ross-Degnan; Christine M Hunter; Carol Mangione; Edward W Gregg Journal: Curr Diab Rep Date: 2018-11-20 Impact factor: 4.810
Authors: J Frank Wharam; Christine Y Lu; Fang Zhang; Matthew Callahan; Xin Xu; Jamie Wallace; Stephen Soumerai; Dennis Ross-Degnan; Joseph P Newhouse Journal: Ann Intern Med Date: 2018-11-20 Impact factor: 25.391
Authors: Anita D Misra-Hebert; Bo Hu; Glen Taksler; Robert Zimmerman; Michael B Rothberg Journal: J Gen Intern Med Date: 2016-04-11 Impact factor: 5.128
Authors: Tannaz Moin; Neil Steers; Susan L Ettner; Kenrik Duru; Norman Turk; Charles Chan; Abigail M Keckhafer; Robert H Luchs; Sam Ho; Carol M Mangione Journal: BMJ Open Diabetes Res Care Date: 2021-01
Authors: O Kenrik Duru; Carol M Mangione; Hector P Rodriguez; Dennis Ross-Degnan; J Frank Wharam; Bernard Black; Abel Kho; Nathalie Huguet; Heather Angier; Victoria Mayer; David Siscovick; Jennifer L Kraschnewski; Lizheng Shi; Elizabeth Nauman; Edward W Gregg; Mohammed K Ali; Pamela Thornton; Steven Clauser Journal: Curr Diab Rep Date: 2018-02-05 Impact factor: 4.810
Authors: Tannaz Moin; Jinnan Li; Kenrik Duru; Susan L Ettner; Norman Turk; Charles Chan; Abigail M Keckhafer; Robert H Luchs; Sam Ho; Carol M Mangione Journal: BMJ Open Diabetes Res Care Date: 2020-04